InterOcean Capital LLC Grows Holdings in Merck & Co., Inc. (NYSE:MRK)

InterOcean Capital LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 17.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,602 shares of the company’s stock after purchasing an additional 966 shares during the quarter. InterOcean Capital LLC’s holdings in Merck & Co., Inc. were worth $508,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sowa Financial Group Inc. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Total Clarity Wealth Management Inc. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $27,000. Stephenson National Bank & Trust purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $28,000. Pacifica Partners Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth $35,000. Finally, Lion Street Advisors LLC purchased a new position in shares of Merck & Co., Inc. during the first quarter valued at $35,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Shares of Merck & Co., Inc. stock traded down $0.18 during trading on Friday, reaching $76.37. The company’s stock had a trading volume of 6,046,385 shares, compared to its average volume of 10,529,766. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82. The company has a market cap of $193.22 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.12 and a beta of 0.50. Merck & Co., Inc. has a 1-year low of $65.25 and a 1-year high of $92.64. The company has a 50-day simple moving average of $79.51 and a two-hundred day simple moving average of $83.36.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, April 28th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.16. The company had revenue of $12.06 billion for the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.22 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 5.31 earnings per share for the current year.

In related news, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $387,702. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.28% of the company’s stock.

A number of research firms recently weighed in on MRK. ValuEngine raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research note on Saturday, February 29th. SVB Leerink lowered their price target on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, April 29th. Guggenheim cut their price objective on shares of Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Royal Bank of Canada lowered their target price on Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating for the company in a report on Wednesday, April 1st. Finally, Mizuho reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a research report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $93.60.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What is Blockchain?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.